China joins global scientists in exploring hadal zone
The Global Hadal Exploration Programme (GHEP), spearheaded by the Institute of Deep-sea Science and Engineering (IDSSE) under the Chinese Academy of Sciences (CAS), aims to transform fragmented hadal research into a coordinated global mission to explore, understand and protect the planet's most inaccessible marine ecosystems.
The hadal zone comprises primarily of ocean trenches, particularly from a depth of 6,000 metres to the bottom of the ocean up to about 11,000 metres.
The hadal environment is characterised by extreme depths and pressures, darkness, low temperatures, frequent earthquakes, and peculiar living forms.
For a long time, the hadal trenches have been among the most under-explored and mysterious areas on earth due to technological limitations.
China has been a key driver of deep-sea exploration over the past decade through sustained sci-tech advancements.
In 2014, the CAS launched the Hadal Science and Technology Programme, followed by a historic dive to the Mariana Trench's 10,000-metre depths in 2016.
By 2022, the CAS initiated the Global Trench Dive and Exploration Programme, leveraging its cutting-edge manned submersible Fendouzhe (Striver) and the Tansuo research vessels.
"Venturing deeper is about understanding our ocean so we can coexist with it," said Du Mengran, a lead researcher at IDSSE.
"Global cooperation in these 'untouched zones' will redefine the boundaries of marine science and provide critical knowledge for deep-sea conservation and sustainable use," she said.
To date, Chinese scientists have collaborated with 145 researchers from 10 countries, exploring nine hadal trenches worldwide, including the Mariana, the Kermadec and Puysegur trenches.
Starting from this year, GHEP will unify international research on extreme environments, life evolution, and geological processes in the hadal zone.
The programme will establish international research hubs, organise joint deep-diving expeditions, and host regular symposia while offering training and open access to samples, data, and facilities – particularly for young scientists, Du added.
GHEP brings together research institutions from New Zealand, Denmark, Germany, Chile, France, Indonesia, Brazil, Russia, India, the Cook Islands, Papua New Guinea, Singapore, Portugal and other countries.
– Bernama
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
a day ago
- The Star
White House unveils artificial intelligence policy plan
WASHINGTON (Reuters) -The White House released an artificial intelligence (AI) policy plan on Wednesday spelling out priorities for the U.S. to achieve "global dominance" in the sector. U.S. President Donald Trump's plan calls for open-source and open-weight AI models to be made freely available by developers for anyone in the world to download and modify. The plan also calls for the Commerce Department to research Chinese AI models for alignment with Chinese Communist Party talking points and censorship. As previously reported by Reuters, it adds the federal government should not allow AI-related federal funding to be directed toward states with "burdensome" regulations. (Reporting by Chris Sanders, writing by Maiya Keidan)
Malaysian Reserve
2 days ago
- Malaysian Reserve
METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting
HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ — METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting. The company demonstrated that its proprietary AiLNP platform enables the rapid design of tissue-targeted lipid nanoparticles (LNPs), which exhibit high delivery efficiency, strong tissue specificity, and excellent translatability in non-human primates (NHPs). Founded in 1978, the Controlled Release Society is the world's foremost nonprofit scientific organization dedicated to advanced drug delivery. At this year's meeting, METiS Technologies stood out as the only Chinese biotechnology company participating with a featured poster presentation. Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS and a Member of the U.S. National Academy of Engineering, together with Dr. Andong Liu, Vice President of METiS, presented the poster titled: 'AI-Empowered LNP Discovery for Organ-Targeted RNA Delivery.' The AiLNP platform is METiS' proprietary AI-driven system for nucleic acid delivery design. It integrates a de novo lipid generation foundation model, a high-throughput microfluidics-based LNP assembly and screening system, and a large-scale, proprietary lipid library. Collectively, these innovations expand the design space of nanomaterials by over 1,000-fold compared to conventional approaches—effectively overcoming long-standing discovery bottlenecks in the field. By combining predictive AI models with molecular dynamics simulations, the AiLNP platform provides mechanistic insights into lipid behavior and enables prediction of more than 10 physicochemical parameters. It further allows for rational design and optimization of LNP components and ratios to construct customized, high-performance delivery systems. Key findings from the poster highlight the platform's ability to accelerate LNP design cycles while significantly improving discovery speed and quality across multiple tissue targets: Liver-targeted LNPs developed through AiLNP demonstrated best-in-class performance for gene editing, achieving high efficiency and safety in NHPs. Using CRISPR-Cas9-mediated TTR knockdown as a model, LNP developed by AiLNP achieved ~90% reduction in serum TTR levels with only a transient, mild elevation in liver enzymes. Lung-targeted LNPs exhibited high delivery efficiency and specificity in rodents, with successful translation to NHPs. At the cellular level, these LNPs transfected a broad range of pulmonary cell types in NHPs—including stem-like cells, alveolar type II cells (>30%), and airway basal cells (>10%) at 1 mg/kg—supporting their potential for durable genetic correction. METiS' Musle-targeted LNPs also enabled successful in vivo delivery and gene editing in multiple types of muscle cells in mice. 'This year's CRS theme, 'Next-Generation Delivery Innovation', reflects the rapid evolution in drug delivery technologies. Among the 410 accepted posters across 12 research tracks, more than 200 focused on nanomedicine, nanodelivery, and gene editing—demonstrating these as the most active areas of exploration,' said Dr. Hongming Chen, Co-founder and Chief R&D Officer of METiS Technologies. 'We're pleased to present our findings at the world's premier scientific forum for drug delivery and remain committed to pushing the boundaries of LNP discovery.' Dr. Chris Lai, Co-founder and CEO of METiS, added: 'Since day one, METiS has been positioning at the global forefront of AI-powered nanomaterial innovation. We believe nanodelivery is the critical enabler of the next generation of programmable medicines—and that AI will be the key catalyst driving this transformation.' AI Nanodelivery for a Healthier Future. METiS Technologies is a pioneering TechBio company at the intersection of artificial intelligence and nanomaterial science, focused on transforming the delivery and application of active agents across life forms. Founded by a team of MIT-trained scientists with deep expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, the company has developed three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design. METiS' platforms simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads. By advancing AI-enabled nanotechnology, METiS strives to unlock new therapeutic possibilities across a wide range of diseases, including cancer, metabolic and autoimmune disorders, and neurodegenerative conditions, and improve the health of lives.
The Star
3 days ago
- The Star
Human brain focuses in quick flickers, not in steady stream: study
JERUSALEM, July 21 (Xinhua) -- Israeli researchers have discovered that the human brain does not pay attention in one smooth stream, but in quick bursts, the Hebrew University of Jerusalem said in a statement on Monday. Although it might seem like the human eyes and brain take in the world in a steady, continuous way, a new study published in Trends in Cognitive Sciences shows otherwise. It was found that attention works more like a strobe light, flickering on and off at a regular rhythm. As people scroll through their phones or switch between tasks, the brain is already doing something similar, the researchers explained. Rather than processing everything at once, it takes rapid mental snapshots, more like a slideshow than a movie. This process, named "attentional sampling," helps the brain handle the constant flood of information. The study found that the brain focuses on visual input around eight times per second. When attention is split between two things, it alternates between them at about four times per second. Attention is always shifting, even when feeling deeply focused. This flickering focus helps the brain manage competing visual inputs by quickly switching between them, often without being aware of it. The idea builds on a long-standing theory called "biased competition," which suggests that different parts of the visual system compete to process information. What drives this rhythm is still unknown, with some scientists believing higher-level brain regions may control the pattern, while others point to local brain circuits. The researchers said this mechanism may apply not just to vision, but to all the senses, and could have wide-reaching implications for interface design, education, and neurological treatments.
